Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$391K Sell
1,553
-100
-6% -$21.5K 0.21% 99
2026
Q1
$360K Buy
1,653
+100
+6% +$22.2K 0.21% 103
2025
Q4
$355K Buy
1,553
+25
+2% +$5.7K 0.22% 102
2025
Q3
$354K Buy
1,528
+23
+2% +$4.68K 0.22% 103
2025
Q2
$279K Hold
1,505
0.19% 108
2025
Q1
$315K Hold
1,505
0.21% 103
2024
Q4
$267K Sell
1,505
-325
-18% -$59.8K 0.18% 110
2024
Q3
$361K Sell
1,830
-5
-0.3% -$933 0.26% 97
2024
Q2
$315K Buy
1,835
+150
+9% +$24.8K 0.24% 104
2024
Q1
$307K Buy
+1,685
New +$290K 0.23% 115
2023
Q4
Sell
-1,371
Closed -$204K 104
2023
Q3
$204K Buy
+1,371
New +$201K 0.19% 100
2023
Q2
Sell
-1,371
Closed -$218K 108
2023
Q1
$218K Hold
1,371
0.21% 102
2022
Q4
$222K Buy
+1,371
New +$210K 0.21% 103
2019
Q4
$86K Buy
+975
New +$80.9K 0.08% 144

Other funds holding ABBV

TI-Trust's ABBV Position: Q2 2026 in Review

TI-Trust reduced its AbbVie (ABBV) stake by 6% in Q2 2026, selling an estimated $21.5K and leaving 1,553 shares worth $391K. The position accounts for 0.21% of the portfolio, ranked #99.

TI-Trust first reported a position in ABBV in Q4 2019 and has held it in 14 quarters since. 1,885 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • TI-Trust held 1,553 shares of AbbVie worth $391K as of Q2 2026.
  • TI-Trust sold 100 AbbVie shares in Q2 2026, an estimated $21.5K.
  • AbbVie made up 0.21% of TI-Trust's portfolio in Q2 2026, its #99 holding.
  • TI-Trust first reported a position in AbbVie in Q4 2019 and has held it in 14 quarters since.
  • 1,885 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on TI-Trust's 13F filing for Q2 2026, filed 23 Jul 2026.